ERAS News and Press, Erasca Inc. From 04/26/23

SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present two poste...

Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred combination dose of naporafenib 200 mg BID plus trametinib 1 mg QD Dosing of first patient in Erasca’s pivotal Phase ...

ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports ‘three weeks on, one week off’ dosing of ERAS-601 Dose expansion data in HPV-negative HNSCC ex...

Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN DIEGO, April 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoverin...

2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...

2023-03-30 09:03:39 ET Cancer-focused biotech Erasca ( NASDAQ: ERAS ) extended gains in the pre-market Thursday after Mizhuho Securities initiated its coverage with a Buy rating and a $9 per share target, citing its upcoming data readouts and liquidity position. “We l...

2023-03-29 13:31:06 ET Cancer-focused biotech Erasca ( NASDAQ: ERAS ) added ~8% on Wednesday, recording the biggest intraday gain since January after its Chief Executive and Chairman Jonathan Lim disclosed the purchase of 100K company shares. According to a regulatory ...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-23 16:40:23 ET Erasca press release ( NASDAQ: ERAS ): Q4 GAAP EPS of -$1.06 misses by $0.77 . Cash, cash equivalents, and marketable securities of $436 million as of December 31, 2022, and anticipated runway into H2 2025 For further details see: Erasc...

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials for ERAS-007, ERAS-601, and ERAS-801 ...